All In MedTech

FDA Clearance Tracker · P950037-S288

Solia CSP S Leads

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 2, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 2, 2026

Approved

Time to decision

30 days

Received Mar 3, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P950037-S288
Device name
Solia CSP S Leads
Applicant location
Lake Oswego, OR
Received
Mar 3, 2026
Decided
Apr 2, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P950037

Device type

Device class
Class III

Every decision under product code NVN

FDA's approval statement

As written in FDA's record.

Approval of the protocol for the post-approval study (PAS) protocol to comply with the conditions of approval outlined in our approval order for P950037/S280.

Source documents

Other decisions for Biotronik, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.